Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
NCT ID: NCT03179943
Last Updated: 2021-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
21 participants
INTERVENTIONAL
2017-11-27
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atezolizumab + Guadecitabine
Atezolizumab
Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
Guadecitabine
Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
Guadecitabine
Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 and ≥ 1 site safe for biopsy.
3. Patient must agree to provide fresh biopsy specimens and peripheral blood samples at the time of screening and during the study.
4. Patients must have received or be ineligible for platinum based chemotherapy and must have received at least one line of therapy with a PD-L1 or PD-1 targeting agent.
5. Age \> 18 years.
6. ECOG performance status ≤ 2
7. Life expectancy ≥ 12 weeks
8. Patients must have normal organ and marrow function as defined below
* Leukocytes \> 3,000/mcL
* Absolute neutrophil count \> 1,500/mcL
* Platelets \> 100,000/mcL
* Hemoglobin \> 9 g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at ≥9.0 g/dL for 7 days or longer)
* Total bilirubin ≤ 2.5 x institutional upper limit of normal (ULN).
* AST/ALT (SGOT/SGPT) \< 2.5 times institutional normal limits unless liver metastases are present in which case AST and ALT must be ≤ 5 x IULN.
* Creatinine within normal institutional limits OR
* Creatinine clearance \> 30 Ml/min (Cockcroft-Gault formula or measured with 24h urine)
* INR or PTT/PT ≤ 1.5 ULN unless patient is on stable therapeutic dose of warfarin
9. Ability to understand and willingness to sign a written informed consent and HIPAA consent document
10. Women of child bearing potential and men must agree to remain abstinent or use adequate contraception (failure rate \<1%) for the duration of study and for 90 days after the completion of the therapy.
Exclusion Criteria
2. Patients receiving any other investigational agents
3. Patients with active or untreated CNS disease. Patients previously treated for CNS disease must be asymptomatic and must not be using steroids for at least 4 weeks prior to starting the study treatment.
4. Patients with active auto-immune disease requiring immunosuppressive medication.
5. Patients treated with systemic immunostimulatory agents (such as interferons, IL 12) within 6 weeks of the start of the treatment or 5 half-lives of the drug, whichever is shorter.
6. Treatment with systemic corticosteroids within 2 weeks prior to the start of the treatment. Patients that require inhaled or low-dose corticosteroids for COPD or asthma, mineralocorticoids are allowed.
7. Patients with active malignancies in addition to urothelial carcinoma.
8. Patients with prior treatment with hypomethylating agents.
9. History of leptomeningeal disease
10. Prior allogeneic stem cell or solid organ transplant.
11. Uncontrolled effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
12. Uncontrolled symptomatic hypercalcemia (\>1.5mmol/L ionized calcium or calcium \> 12mg/dl or corrected serum calcium \> ULN)
13. Mean QT interval corrected for heart rate (QTc) ≥ 470ms calculated from 3 ECGs using Frediricia's correction.
14. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1 except for endocrine AEs managed with replacement therapy. Any other AEs unresolved toxicities grade 2 or more from previous anti-cancer therapy, except alopecia, peripheral neuropathy or non-clinically significant lab abnormalities.
15. Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to the start of the study treatment.
16. Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
17. History of severe allergic, anaphylactic or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
18. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterations), drug-induced pneumonitis or idiopathic pneumonitis or evidence of interstitial lung disease or active non-infectious pneumonitis.
19. Active tuberculosis
20. Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs.
21. Administration of a live, attenuated vaccine within 4 weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the study.
22. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
23. Known HIV-positive patients on combination antiretroviral therapy are ineligible.
24. Known history of HBV or HCV infection.
25. Pregnant or breast feeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stand Up To Cancer
OTHER
Van Andel Research Institute
OTHER
Fox Chase Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USC Norris Hospital and Clinics
Los Angeles, California, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SU2C-AACR-CT08-17
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
GU-114
Identifier Type: -
Identifier Source: org_study_id